Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43974   clinical trials with a EudraCT protocol, of which   7312   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    The intraoperative use of fluorescent tracers and multimodal imaging techniques in treatment of head and neck cancer

    Summary
    EudraCT number
    2013-003578-28
    Trial protocol
    DK  
    Global end of trial date
    20 Jan 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    27 May 2018
    First version publication date
    27 May 2018
    Other versions
    Summary report(s)
    Study 1
    Study 2 - Study repport

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    2013070001
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    -
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Rigshospitalet
    Sponsor organisation address
    Blegdamsvej 9, Copenhagen, Denmark, 2100
    Public contact
    Department of Clinical Clinical Physiology, Nuclear Medine & PET , Rigshospitalet, 0045 35454216, andreas.kjaer@regionh.dk
    Scientific contact
    Department of Clinical Clinical Physiology, Nuclear Medine & PET , Rigshospitalet, 0045 35454216, andreas.kjaer@regionh.dk
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    08 Mar 2018
    Is this the analysis of the primary completion data?
    Yes
    Primary completion date
    20 Jan 2017
    Global end of trial reached?
    Yes
    Global end of trial date
    20 Jan 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    To examine and implement the intraoperative use of fluorescent tracers and optical imaging in the treatment of oral cancer. Study 1: Near-infrared Fluorescence Tracer Imaging in sentinel Node Biopsi for oral cavity cancer patients Study 2: Near-infrared Fluorescence assisted neck dissection in oral cancer
    Protection of trial subjects
    I accordance with national ethical approval
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    01 Oct 2013
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Denmark: 61
    Worldwide total number of subjects
    61
    EEA total number of subjects
    61
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    41
    From 65 to 84 years
    20
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Patients with primary oral cancer referred to Rigshospitalet for surgery as first treatment modality Study 1: Patients planed for SNB-staging surgery Study 2: Patients planed for therapeutic neck dissction

    Pre-assignment
    Screening details
    Histology verified squamous cell carcinoma of the oral cavity CT and/or MRI og the neck

    Period 1
    Period 1 title
    over-all trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    NIRF-Neck
    Arm description
    Study 2: Arm 1: NIR-Fluorescence-guided neck dissection
    Arm type
    Experimental

    Investigational medicinal product name
    Indocyanine Green
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for injection/infusion
    Routes of administration
    Soft tissue use
    Dosage and administration details
    Study 1: 0,05 mg ICG STudy 2: 0,2 mg ICG

    Arm title
    Conventional neck dissection
    Arm description
    Study 2 Arm 2: Cenventional neck dissection
    Arm type
    conventional surgery

    Investigational medicinal product name
    No investigational medicinal product assigned in this arm
    Arm title
    Study 1 - NIRF-SNB
    Arm description
    One arm study
    Arm type
    Feasibility - no control arm

    Investigational medicinal product name
    Indocyanine Green
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Concentrate and solvent for solution for injection/infusion
    Routes of administration
    Soft tissue use
    Dosage and administration details
    Study 1: 0,05 mg ICG STudy 2: 0,2 mg ICG

    Number of subjects in period 1
    NIRF-Neck Conventional neck dissection Study 1 - NIRF-SNB
    Started
    16
    15
    30
    Completed
    16
    15
    30

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    over-all trial
    Reporting group description
    -

    Reporting group values
    over-all trial Total
    Number of subjects
    61 61
    Age categorical
    Units: Subjects
        In utero
    0
        Preterm newborn infants (gestational age < 37 wks)
    0
        Newborns (0-27 days)
    0
        Infants and toddlers (28 days-23 months)
    0
        Children (2-11 years)
    0
        Adolescents (12-17 years)
    0
        Adults (18-64 years)
    0
        From 65-84 years
    0
        85 years and over
    0
    Age continuous
    Units: years
        arithmetic mean (standard deviation)
    62 ± 3 -
    Gender categorical
    Units: Subjects
        Female
    20 20
        Male
    41 41

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    NIRF-Neck
    Reporting group description
    Study 2: Arm 1: NIR-Fluorescence-guided neck dissection

    Reporting group title
    Conventional neck dissection
    Reporting group description
    Study 2 Arm 2: Cenventional neck dissection

    Reporting group title
    Study 1 - NIRF-SNB
    Reporting group description
    One arm study

    Primary: Study 1: Additional sentinel nodes identified by NIRF-guidance.

    Close Top of page
    End point title
    Study 1: Additional sentinel nodes identified by NIRF-guidance. [1] [2]
    End point description
    Study 1: Additional sentinel nodes only identified due to the additional use of NIR fluorescence intraoperatively
    End point type
    Primary
    End point timeframe
    post-surgery
    Notes
    [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The endpoint in study 1 is additional sentinel lymph nodes identified due to use of NIRF imaging - no analysis kan be presented apart from a numerical number.
    [2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint in study 1 is additional sentinel lymph nodes identified due to use of NIRF imaging - no analysis kan be presented apart from a numerical number.
    End point values
    Study 1 - NIRF-SNB
    Number of subjects analysed
    30
    Units: number of lymph nodes
    11
    No statistical analyses for this end point

    Primary: Study 2: Number of lymph nodes in the neck dissecion specimen from level Ib-III

    Close Top of page
    End point title
    Study 2: Number of lymph nodes in the neck dissecion specimen from level Ib-III [3] [4]
    End point description
    study 2: Number of lymph nodes harvested in the neck dissecion specimen in level Ib-III
    End point type
    Primary
    End point timeframe
    post-operatively
    Notes
    [3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.
    Justification: The endpoint in study 2 is simple the number of harvested lymph nodes in the control Group vs. the NIRF-Neck Group. The stastistics is reported in the attachment report.
    [4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
    Justification: The endpoint is simple the number of harvested lymph nodes in the control Group vs. the NIRF-Neck Group. The stastistics is reported in the attachment report.
    End point values
    NIRF-Neck Conventional neck dissection
    Number of subjects analysed
    16 [5]
    15 [6]
    Units: number of lymph nodes
    406
    317
    Notes
    [5] - 16 patients and 17 neck-sides for analysis
    [6] - 15 patients and 17 neck sides for evaluation
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information [1]
    Timeframe for reporting adverse events
    From time of injection of tracer substance to two weeks post-surgery
    Adverse event reporting additional description
    No adverse events was recorded
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    clinical examination
    Dictionary version
    1
    Frequency threshold for reporting non-serious adverse events: 0%
    Notes
    [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
    Justification: No adverse events was seen.

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    None

    Online references

    http://www.ncbi.nlm.nih.gov/pubmed/26467454
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA